Core Viewpoint - Huaxi Biological (688363.SH) announced that its controlling shareholder, Huaxi Xinyu, has cumulatively increased its stake in the company by 3.4969 million shares, representing 0.73% of the total share capital, with a total investment amount of 201 million yuan. The share buyback plan has not yet been fully implemented [1] Summary by Category - Shareholding Increase - Huaxi Xinyu has increased its holdings by 3.4969 million shares [1] - This increase accounts for 0.73% of the company's total share capital [1] - The total amount invested in this share increase is 201 million yuan [1] - Implementation Status - The share buyback plan is still in progress and has not been fully executed [1]

Core Viewpoint - The controlling shareholder of Huaxi Biological, Huaxi Xinyu, has increased its stake in the company by acquiring 3.4969 million shares, representing 0.73% of the total share capital, with a total investment of 201 million yuan, and the buyback plan is not yet completed [1] Summary by Relevant Sections - **Shareholding Increase** - Huaxi Xinyu has cumulatively increased its holdings by 3.4969 million shares [1] - This increase accounts for 0.73% of the total share capital of Huaxi Biological [1] - The total amount invested in this share acquisition is 201 million yuan [1] - **Buyback Plan Status** - The share buyback plan by Huaxi Xinyu is still in progress and has not been fully executed [1]

证券代码：688363 证券简称：华熙生物 公告编号：2025-034 华熙生物科技股份有限公司 关于控股股东增持股份进展暨增持金额超过区间下 限的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 已披露增持计划情况：华熙生物科技股份有限公司（以下简称"华熙生 物""公司"）的控股股东华熙昕宇投资有限公司（以下简称"华熙昕宇"） 基于对公司未来发展的信心和长期投资价值认可，计划自 2025 年 8 月 8 日起的 6 个月内，使用自有资金或自筹资金，通过上海证券交易所系统允许的方式（包 括但不限于集中竞价、大宗交易等）增持公司股份，增持金额不低于人民币 2 亿元（含），不超过人民币 3 亿元（含），增持股份比例不超过公司总股本 1%， 增持股票价格不超过 70 元/股。具体内容详见公司于 2025 年 8 月 8 日在上海证 券交易所网站（www.sse.com.cn）披露的《华熙生物科技股份有限公司关于控股 股东增持公司股份计划公告》（公告编号：2025-028）。 增持计划的实施情况：截至 2 ...

Group 1 - The core point of the article is that Huaxi Bio (688363.SH) has announced a share buyback plan, with Huaxi Xinyu having increased its holdings by 3.4969 million shares, representing 0.73% of the total share capital [1] - The total amount spent on the share buyback has reached RMB 201 million, exceeding the lower limit of the planned buyback amount of RMB 200 million [1] - The buyback plan is still in progress and has not yet been fully implemented [1]

Core Viewpoint - The article emphasizes the need for companies, particularly Huaxi Biological, to adapt and innovate in a rapidly changing market environment, focusing on scientific evidence and technological strength to regain market leadership in skin science innovation [4][5][6]. Group 1: Company Strategy and Leadership - Zhao Yan, the leader of Huaxi Biological, acknowledges past mistakes in market awareness and emphasizes the importance of a strong operational team to navigate the competitive landscape [3][4]. - The company is shifting its focus from merely being known for hyaluronic acid to positioning itself as a synthetic biotechnology firm with a robust research and development foundation [5][16]. - Huaxi Biological aims to stabilize its core business while exploring new product categories, leveraging its significant investment in a large-scale synthetic biology pilot platform [6][26]. Group 2: Marketing and Brand Strategy - The company has faced declining revenue and profit margins in its functional skincare segment from 2022 to 2024, prompting a reevaluation of its marketing strategies [8]. - Zhao Yan has restructured the brand division to emphasize skin science and health, moving away from reliance on high-profile influencers to a more diversified marketing approach [9][10]. - The company is focusing on scientific communication in its marketing efforts, aiming to clarify the benefits of its products based on research data rather than vague marketing jargon [10][13]. Group 3: Research and Development Focus - Huaxi Biological has invested heavily in R&D, establishing a state-of-the-art research center to support its product development and quality assurance processes [11][18]. - The company is expanding its research into glycoscience and cell biology, with a focus on developing new materials that can address aging and tissue regeneration [19][20]. - The strategic decision to develop a range of glycan-based products reflects the company's commitment to innovation and its understanding of market demands for new anti-aging solutions [20][21]. Group 4: Market Position and Future Outlook - The company is positioned to capitalize on the growing demand for synthetic biology products, with a focus on overcoming the challenges of scaling production from laboratory to market [23][24]. - Huaxi Biological's investment in a flexible pilot platform is seen as a critical infrastructure for the synthetic biology industry, enabling faster and more efficient product development [26]. - The company aims to maintain its entrepreneurial spirit and adaptability in the face of market fluctuations, emphasizing the importance of scientific integrity over marketing hype [27].

Core Insights - The core viewpoint of the articles revolves around the challenges and strategic shifts faced by Huaxi Biological, particularly under the leadership of Zhao Yan, as the company aims to regain its market position in the highly competitive beauty and medical aesthetics industry while leveraging its scientific capabilities in synthetic biology [1][2][9]. Group 1: Company Challenges and Strategic Shifts - Huaxi Biological's revenue and gross margin from functional skincare products have been declining from 2022 to 2024, impacting market confidence [3]. - Zhao Yan acknowledges internal issues in team building and organizational capabilities that have led to ineffective marketing investments, emphasizing the need for a more scientific and rational approach to market communication [4][8]. - The company is transitioning from reliance on high-profile influencers to a more diversified marketing strategy, focusing on mid-tier influencers to enhance brand presence and consumer engagement [4][5]. Group 2: R&D and Technological Advancements - Huaxi Biological has invested significantly in R&D, with a state-of-the-art research center in Jinan, equipped with advanced analytical instruments to support its raw material research and quality control [6][11]. - The company is expanding its product development into various biological materials, including collagen and other glycan-based substances, leveraging its expertise in synthetic biology [9][12]. - The establishment of a large-scale synthetic biology pilot platform in Tianjin, costing 3 billion yuan, aims to bridge the gap between laboratory research and large-scale production, addressing the challenges of scaling up biomanufacturing processes [18]. Group 3: Market Position and Future Outlook - Huaxi Biological's core product, hyaluronic acid, remains a significant revenue driver, but the company is also focusing on new concepts in the market, such as recombinant collagen, to meet evolving consumer demands [9][10]. - The company is positioning itself as a leader in synthetic biology, with a strategic focus on developing a comprehensive ecosystem that includes partnerships with academic institutions and other biotech firms [11][13]. - Zhao Yan's leadership is characterized by a return to entrepreneurial spirit, aiming to replicate the success of hyaluronic acid across multiple product lines, thus enhancing the company's growth potential in the biomanufacturing sector [14][16].

Core Insights - The medical beauty industry is witnessing a competitive showdown between two leading companies, Juzhi Biotechnology and Huaxi Biotechnology, with contrasting financial performances in the first half of 2025 [1][8][14] - Juzhi Biotechnology reported a revenue of 3.113 billion RMB and a net profit of 1.182 billion RMB, achieving a net profit margin of 38%, while Huaxi Biotechnology experienced a 19.57% decline in revenue to 2.261 billion RMB and a 35.38% drop in net profit to 221 million RMB, marking its worst performance in seven years [1][8] Juzhi Biotechnology: Growth Drivers and Potential Concerns - Juzhi's growth is attributed to the synergy of products, channels, and brand, with professional skin care products accounting for 99.7% of total revenue [3][4] - The revenue from functional skin care products reached 2.410 billion RMB, a 24.2% increase year-on-year, primarily driven by the sales of key products [3][4] - Despite strong revenue growth, the company faces challenges such as a slight decrease in gross margin to 81.7% and increased sales and administrative expenses, leading to a rise in overall expense ratio to 38.8% [3][4][5] - The company heavily relies on its two main brands, Kefu Mei and Keli Jin, which together contribute 97.8% of revenue, raising concerns about its growth potential and risk exposure [5][6] Huaxi Biotechnology: Struggles and Strategic Reforms - Huaxi's performance has been under pressure, with a significant decline in its functional skin care segment, which accounts for over 40% of its business, down 34% [8][9] - The company has implemented drastic cost-cutting measures, reducing sales expenses by 39.86% in the second quarter, and has shifted its focus from scale to efficiency in brand promotion [9][10] - Huaxi has also streamlined its R&D efforts by eliminating 88 non-technical brand incubation projects and reallocating resources towards high-barrier products and medical terminal businesses [10][11] - Despite these reforms, Huaxi faces ongoing challenges, including a shrinking traditional hyaluronic acid market and the need for new high-end products to achieve significant sales [11][12] Industry Dynamics and Future Outlook - The competition between Juzhi and Huaxi reflects a broader shift in the medical beauty industry from marketing-driven growth to a focus on technological advancements and product innovation [14][15] - As regulatory scrutiny increases and consumer demand for genuine technological efficacy rises, both companies must adapt their strategies to maintain competitive advantages [14][15] - The outcome of this rivalry will serve as a critical case study for the industry, highlighting the importance of balancing marketing with substantial R&D investments to ensure long-term sustainability [15]

Group 1 - The medical beauty sector experienced a rise of 3.39% on September 5, with Ai Meike leading the gains [1] - The Shanghai Composite Index closed at 3812.51, up 1.24%, while the Shenzhen Component Index closed at 12590.56, up 3.89% [1] - Major stocks in the medical beauty sector showed varied performance, with Ai Meike closing at 190.83, up 3.67%, and Huaxi Biological closing at 57.14, up 3.23% [1] Group 2 - The medical beauty sector saw a net inflow of 36.38 million yuan from institutional investors, while retail investors experienced a net outflow of 44.71 million yuan [1] - The trading volume for Ai Meike was 45,900 hands, with a transaction amount of 858 million yuan [1] - The stock performance of other companies in the sector included *ST Meigu, which closed at 3.17, up 0.63%, and Jinbo Biological, which closed at 302.39, down 0.86% [1]

Core Viewpoint - Huaxi Biological has reported its worst semi-annual financial results since going public, with significant declines in both revenue and net profit, indicating a challenging period for the company [1][6]. Financial Performance - In the first half of 2025, Huaxi Biological's revenue was 2.26 billion yuan, a year-on-year decrease of 19.57% [2]. - The net profit attributable to shareholders was 220.85 million yuan, down 35.38% year-on-year, with a 45% decline in net profit after excluding non-recurring gains and losses [2][1]. - The company's total assets decreased by 0.97% compared to the previous year, while net assets attributable to shareholders increased by 3.27% [2]. Organizational Changes - The company is undergoing significant internal restructuring, with reports of major layoffs, particularly in the teams of its skincare brands, which have seen staff numbers drop from over a hundred to just a few dozen [2][24]. - The return of founder Zhao Yan has led to a wave of organizational changes, including the departure of over 10 senior executives and a shift towards a more entrepreneurial management style [4][28]. Market Position and Strategy - Huaxi Biological, once a leader in the hyaluronic acid market with a 44% global market share, has seen its competitive edge erode, leading to a decline in its skincare product sales [8][11]. - The company’s functional skincare products generated 4.61 billion yuan in sales in 2022, but this segment has faced a significant downturn, with a 31.62% year-on-year decline in 2024 [9][11]. - The company is shifting its focus from a reliance on influencer marketing to a more sustainable business model, as the previous strategies have become less effective in a competitive market [12][30]. Internal Challenges - Huaxi Biological is facing a crisis of trust internally, with allegations of financial misconduct and workplace bullying surfacing, further complicating its operational challenges [17][26]. - The company has implemented strict measures against corruption, demanding accountability from its staff and restructuring its management to restore confidence [21][28]. Future Outlook - While Zhao Yan's return has sparked hope for a turnaround, the company still faces significant challenges in a competitive market, with consumer preferences shifting away from hyaluronic acid products [30][32]. - The performance of Huaxi Biological in the coming quarters will be critical in determining the effectiveness of its restructuring efforts and market strategy [32].

Core Viewpoint - The performance of various domestic beauty brands in the first half of the year shows a mixed picture, with some brands experiencing growth while others struggle with declining revenues and profits as the industry faces intensified competition and the end of the traffic dividend era [1][3][5]. Financial Performance - Up to now, several domestic beauty brands have reported their half-year results, with Proya, Shangmei, Mao Geping, and Shuiyang showing increases in both revenue and net profit [1]. - Shangmei's revenue reached 4.108 billion yuan, a year-on-year increase of 17.3%, with a net profit of 524 million yuan, up 30.65% [3]. - Mao Geping reported revenue of 2.588 billion yuan, a 31.3% increase, and a net profit of 670 million yuan, up 36.1% [3]. - Shuiyang's revenue was 2.5 billion yuan, growing 9.02%, with a net profit of 123 million yuan, up 16.54% [3]. - Proya's revenue was 5.362 billion yuan, a 7.21% increase, and a net profit of 799 million yuan, up 13.8%, but growth rates have slowed compared to previous years [3][4]. - Conversely, Beitaini and Yixian E-commerce continue to face growth challenges, with Beitaini's revenue down 15.43% to 2.372 billion yuan and net profit down 49.01% to 247 million yuan [4][5]. Strategic Adjustments - Beitaini is focusing on strategic adjustments and operational optimization, emphasizing high-value products and quality growth, which has led to improved gross margins and cash flow despite short-term revenue impacts [4][5]. - Yixian E-commerce is pursuing a strategic transformation driven by innovation, aiming to enhance product competitiveness through collaborative innovation among multiple brands [4][5]. - Proya is adopting a multi-brand strategy, acquiring various brands to strengthen its market position, including cosmetic brands and medical supplies [5][6]. Market Trends - The domestic beauty industry is witnessing a shift from high marketing-driven growth to a focus on strategic brand positioning and international expansion as the traffic dividend diminishes [5][9]. - Brands are increasingly looking for overseas growth opportunities, with Proya planning to issue H-shares for international expansion and Beitaini establishing regional headquarters in Thailand [9][10]. - Water Sheep is also pursuing a high-end transformation by acquiring luxury brands to enhance its market presence [6][10]. Competitive Landscape - The beauty industry is facing intensified competition, with brands needing to adapt to changing consumer behaviors and market dynamics [5][9]. - The low-price competition strategy adopted by Shangmei has raised concerns about its long-term sustainability as consumer rationality increases [7][9]. - Experts suggest that domestic beauty brands must enhance their brand structure and user value to compete effectively on a global scale [10].